| Literature DB >> 31210778 |
Ari Leppäniemi1, Matti Tolonen1, Antonio Tarasconi2, Helmut Segovia-Lohse3, Emiliano Gamberini4, Andrew W Kirkpatrick5, Chad G Ball5, Neil Parry6, Massimo Sartelli7, Daan Wolbrink8, Harry van Goor8, Gianluca Baiocchi9, Luca Ansaloni10, Walter Biffl11, Federico Coccolini10, Salomone Di Saverio12, Yoram Kluger13, Ernest Moore14, Fausto Catena2.
Abstract
Although most patients with acute pancreatitis have the mild form of the disease, about 20-30% develops a severe form, often associated with single or multiple organ dysfunction requiring intensive care. Identifying the severe form early is one of the major challenges in managing severe acute pancreatitis. Infection of the pancreatic and peripancreatic necrosis occurs in about 20-40% of patients with severe acute pancreatitis, and is associated with worsening organ dysfunctions. While most patients with sterile necrosis can be managed nonoperatively, patients with infected necrosis usually require an intervention that can be percutaneous, endoscopic, or open surgical. These guidelines present evidence-based international consensus statements on the management of severe acute pancreatitis from collaboration of a panel of experts meeting during the World Congress of Emergency Surgery in June 27-30, 2018 in Bertinoro, Italy. The main topics of these guidelines fall under the following topics: Diagnosis, Antibiotic treatment, Management in the Intensive Care Unit, Surgical and operative management, and Open abdomen.Entities:
Keywords: Acute pancreatitis; Consensus statement; Infected necrosis; Necrosectomy; Open abdomen
Mesh:
Substances:
Year: 2019 PMID: 31210778 PMCID: PMC6567462 DOI: 10.1186/s13017-019-0247-0
Source DB: PubMed Journal: World J Emerg Surg ISSN: 1749-7922 Impact factor: 5.469
Grading of Recommendations Assessment, Development and Evaluation (GRADE) hierarchy of evidence from Guyatt et al. [5]
| Grade of recommendation | Clarity of risk/benefit | Quality of supporting evidence | Implications |
|---|---|---|---|
| 1A | |||
| Strong recommendation, high-quality evidence | Benefits clearly outweigh risk and burdens, or vice versa | RCTs without important limitations or overwhelming evidence from observational studies | Strong recommendation, applies to most patients in most circumstances without reservation |
| 1B | |||
| Strong recommendation, moderate-quality evidence | Benefits clearly outweigh risk and burdens, or vice versa | RCTs with important limitations (inconsistent results, methodological flaws, indirect analyses or imprecise conclusions) or exceptionally strong evidence from observational studies | Strong recommendation, applies to most patients in most circumstances without reservation |
| 1C | |||
| Strong recommendation, low-quality or very low-quality evidence | Benefits clearly outweigh risk and burdens, or vice versa | Observational studies or case series | Strong recommendation but subject to change when higher quality evidence becomes available |
| 2A | |||
| Weak recommendation, high-quality evidence | Benefits closely balanced with risks and burden | RCTs without important limitations or overwhelming evidence from observational studies | Weak recommendation, best action may differ depending on the patient, treatment circumstances, or social values |
| 2B | |||
| Weak recommendation, moderate-quality evidence | Benefits closely balanced with risks and burden | RCTs with important limitations (inconsistent results, methodological flaws, indirect or imprecise) or exceptionally strong evidence from observational studies | Weak recommendation, best action may differ depending on the patient, treatment circumstances, or social values |
| 2C | |||
| Weak recommendation, Low-quality or very low-quality evidence | Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced | Observational studies or case series | Very weak recommendation; alternative treatments may be equally reasonable and merit consideration |
Definition of severity in acute pancreatitis
| Revised Atlanta Classification (RAC) | Determinant-based classification (DBC |
|---|---|
| Mild acute pancreatitis (AP) | Mild AP |
| No organ failure | No organ failure AND |
| No local or systemic complications | No (peri)pancreatic necrosis |
| Moderately severe AP | Moderate AP |
| Transient organ failure (< 48 h) | Transient organ failure AND/OR |
| Local or systemic complications without persistent organ failure | Sterile (peri)pancreatic necrosis |
| Severe AP | Severe AP |
| Persistent single or multiple organ | Persistent organ failure OR |
| failure (> 48 h) | Infected (peri)pancreatic necrosis |
| Critical AP | |
| Persistent organ failure AND | |
| Infected (peri)pancreatic necrosis |
CT Severity Index (Modified from: Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology. 1990; 174:331–6 [27])
| CT grade | Grade score | Definition |
| A | 0 | Normal pancreas |
| B | 1 | Pancreatic enlargement |
| C | 2 | Pancreatic inflammation and/or peripancreatic fat |
| D | 3 | Single peripancreatic fluid collection |
| E | 4 | ≥ 2 fluid collections and/or retroperitoneal air |
| % of necrosis | Necrosis score | Definition |
| None | 0 | Uniform pancreatic enhancement |
| < 30% | 2 | Non-enhancement of region(s) of gland equivalent in size of pancreatic head |
| 30–50% | 4 | Non-enhancement of 30–50% of the gland |
| > 50% | 6 | Non-enhancement of over 50% of the gland |
| CT Severity Index | Morbidity | Mortality |
| 0–1 | 0 | 0 |
| 2–3 | 8% | 3% |
| 4–6 | 35% | 6% |
| 7–10 | 92% | 17% |
CT severity Index = grade score (0–4) + necrosis score (0–6)
Bedside index of severity of acute pancreatitis (BISAP) score [48]
| BISAP: score one point for each of the following criteria | |
|---|---|
| Blood urea nitrogen level > 8.9 mmol/L | |
| Impaired mental status | |
| Systemic inflammatory response syndrome is present | |
| Age > 60 years | |
| Pleural effusion on radiography |